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Research has been described as “a powerful means of achieving” the objectives of the 
Department of Health, namely “to improve the health and well-being of the population and to 
secure high quality care.”1 There is, however, a need to find a balance between facilitating 
important research and protecting the confidentiality of patients. As the capabilities of 
information technology grow, legal frameworks and professional guidance need to be created 
or refined to safeguard the rights of patients. 
Some areas of the common law duty of confidentiality and the new Data Protection Act 1998, 
which constitutes the United Kingdom's implementation of the relevant European Union 
directive,
2
  are causing difficulties of interpretation within the NHS. With few exceptions, 
broad debate about the implications of the new act is lacking, particularly in the context of 
epidemiological research that uses patients' records.
3
 Questions of consent, anonymisation of 
data for research, and access to medical notes for research purposes (rather than audit) have 
been addressed in a range of literature.
4
9-13 Some of these documents are being updated; this 
may indicate that there are uncertainties about the legal issues involved in implementing the 
act. Local variations in interpretation may cause particular difficulties for researchers 
conducting multicentre epidemiological studies, as the case study that will be described in 
this article shows. 
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In the meantime, those who must make decisions about confidentiality are still confused. This 
confusion exists for several reasons. Firstly, there is the interpretation of the act (and to an 
extent the common law duty of confidentiality). The interpretation is subject to debate, and 
no case law exists which might clarify the interpretation. Secondly, there is a dearth of up to 
date and clear policy guidance. Thirdly, the new system of “Caldicott guardians”  is untried, 
and guardians as well as others are only beginning to learn to exercise their new 
responsibilities. Fourthly, clarification is needed about the role that research ethics 
committees should have in data protection and confidentiality. Guidance recently issued by 
the NHS should help clarify some of these areas.
5
 We highlight issues for future discussion 
that have arisen in a case study of a multicentre epidemiological project that sought to use 
patients' records. 
Summary points 
 The interpretation of the Data Protection Act 1998 and how it affects the NHS, 
healthcare, and epidemiological research is riddled with uncertainties 
 Clarification is needed to determine how the common law duty of confidentiality 
affects the health sector in terms of using patients' data for research 
 Different interpretations of the act and the duty of confidentiality may adversely affect 
the ability of researchers to conduct multicentre studies. 
Case study 
Regional NHS sources funded our department in collaboration with clinicians from five NHS 
trusts to undertake a retrospective pragmatic study of the effectiveness and cost effectiveness 
of a new drug treatment. In the initial phase it was expected that a registered nurse employed 
by the university would extract data on treatment and on the utilisation of health services 
from the routine records of patients seen in collaborating trusts. 
The relevant multicentre research ethics committee approved the study but advised the 
researchers that the question of whether explicit consent was needed from patients to allow 
the researchers to have access to the medical records needed to be clarified with data 
protection officers at the five hospital trusts. The responses to this request are shown in the 
box (p 891). The trusts' decisions varied considerably and usually involved complex internal 
discussions and consultation; consequently, this led to delays. 
Does the diversity in the outcomes mean that some trusts made erroneous judgments or that 
the law is ambiguous, or can the situations in individual trusts be sufficiently different for 
them to reach contrary decisions? Although the latter case seems unlikely, there are 
individual circumstances under which trusts may arrive at a different decision about the same 
project. One such condition may involve cases in which trusts have in place routine 
mechanisms to obtain consent from patients for the use of their personal data for future 
research, a procedure which would be subject to the approval of a research ethics committee. 
Explanation of terms 
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Data Protection Act 1998—This brings into UK law European Directive 95/46/EC on the 
processing of personal data. It came into effect on 1 March 2000, and in comparison with the 
1984 act (which it replaces) it is concerned with both records on paper and records held on 
computers. The act is based on eight principles the first of which stipulates that “personal 
data shall be processed fairly and lawfully.” Interpretation of the phrase “fairly and lawfully” 
may give rise to different opinions about implementation. 
Common Law Duty of Confidentiality—This legal duty applies to information entrusted to 
someone in confidence. The duty of confidentiality applies independently of the Data 
Protection Act. The Department of Health acknowledges that there are conflicting legal views 
on applying this duty and is trying to interpret it for the health sector.
6
 In particular, the issue 
of consent and the conditions under which consent can be implied or waived need to be 
clarified. 
Caldicott guardian—In 1997 the Caldicott Committee reported on its review of information 
that identifies NHS patients.4 In keeping with the report's main recommendations each health 
authority, trust, and primary care group in the United Kingdom appointed a “Caldicott 
guardian.” One key responsibility of the guardians is to agree and review internal protocols 
for the protection and use of identifiable information obtained from patients.
7
 
Trusts' decisions on whether patients needed to give explicit consent 
Trust 1—This trust decided that the researcher could have access to patients' records without 
explicit consent from patients as long as no identifiable information was removed from the 
hospital (for example, the researcher could extract information from records and retain it in 
coded form but the key for decoding would be kept at the hospital). (Time to decision: <3 
weeks.) 
Trust 2—The Caldicott guardian decided that consent from patients was required. This 
decision was later revised after the trust sought legal advice, and the researcher was then 
permitted to have access to patients' records because the Data Protection Act 1998 only came 
into force after the start of the study (1 March 2000). (Time to decision: 4-5 months.) 
Trust 3—The data protection officer and the Caldicott guardian advised the researcher to 
obtain explicit consent from patients because the researcher was not a staff member of the 
trust and no explicit consent exists from patients to permit the use of their data for research 
(for example, no agreements are signed by patients when they are first seen). (Time to 
decision: 6 weeks.) 
Trust 4—The data protection officer immediately decided that the proposed study required 
explicit consent from patients since only staff with a duty of care to the patient are permitted 
to have access to that patient's medical records, and, unlike audit, research is not seen as part 
of the healthcare process. (Time to decision: immediate.) 
Trust 5—The data protection officer made a formal decision only about records held on the 
computer. The outsider status of the researcher was problematic. The case of deceased 
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patients (which is not covered by the Data Protection Act) would have to be decided by the 
research ethics committee. (Time to decision: no formal decision at 7 weeks.) 
As a result of the trusts' decisions there seemed to be three options available to the 
researchers: abandon the project entirely, seek explicit consent from patients who have been 
treated in the trusts that demand explicit consent, or alter the design of the study so that only 
anonymised data are used. 
Discussion 
Issues of consent, anonymisation, and access to patients' records for research need to be more 
widely discussed and evaluated in terms of the 1998 act and the Common Law Duty of 
Confidentiality. Well meaning clinicians may be passing anonymised or non-anonymised 
data to researchers without realising the legal implications. 
It is not easy to answer questions about data protection requirements for particular research 
projects, and many individuals within trusts who are responsible for tackling these questions 
face difficulties in answering them. Because of the current uncertainty, insurmountable 
problems may arise in cases in which researchers hope to conduct their studies at a variety of 
centres, especially since they may have to comply with conflicting interpretations of the 
existing law and conflicting guidance from various bodies. This situation has created 
inconsistencies in the access to routine NHS data allowed to researchers. Additionally, the 
appropriate interactions between the new Caldicott guardians, the data protection officers in 
each trust, clinicians, and research ethics committees has not yet been fully clarified; 
however, a revision of the guidance for local research ethics committees is expected to be 
published later in the year and may partially address this problem.
8
 Also, anxieties about the 
requirements for consent have increased as a result of the exposure of cases in which organs 
were retained for research and medical research procedures were performed on children.
9
 
One of the options for resolving the issue of consent in our case study was to use anonymous 
data. A High Court decision in May 1999 increased uncertainty in the healthcare and medical 
research communities about the legality of processing even fully anonymised data without 
consent
10
 18: in this case the judge held that confidentiality can be breached even when 
anonymisation is used if the patient has not consented and the research is not in the public 
interest (in this case, data were being sold by pharmacists indirectly to the pharmaceutical 
industry). The Court of Appeal overturned the judge's decision in December 1999, ruling that 
as a reasonable pharmacist's conscience would not be troubled by the proposed use of the 
information any claim for breach of confidentiality was unlikely to be successful.
11
 
Unfortunately this aspect of the law remains unresolved because leave may be given to 
appeal to the House of Lords. 
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The view of the data protection commissioner is that any personal data which has been 
encoded remains personal data in the sense of the Data Protection Act 1998 provided that the 
key for decoding it remains in existence. Thus, coded data falls within the scope of the Data 
Protection Act even if the key for decoding it is not accessible to the researcher. The new 
NHS number being assigned to patients is an example of such a code, and chronic disease 
registers and reporting systems or postmarketing surveillance systems of new drug treatments 
might use codes that can be linked to individuals. Much epidemiological research and 
research into health economics would simply be impossible to conduct if completely 
anonymous data had to be used because updating, linking, or validating data is impossible 
without using codes. 
The processing of coded personal data (sometimes called “pseudonymised” data to 
distinguish it from fully anonymised data) for research does not necessarily contravene the 
act. However, in considering whether data processing is “fair and lawful” routine 
mechanisms to merely inform patients in advance about the potential use of their personal 
data for future research (for example, through form letters or notices posted in waiting rooms) 
may not be seen as constituting sufficient consent. It is also unclear whether patients who do 
not register their refusal can be said to have consented. Neither the Data Protection Act 1998 
nor the confidentiality law give sufficient guidance as to what constitutes explicit and implied 
consent and when each ought to be used. 
Strict, clear criteria are urgently needed to determine under which limited situations such 
consent requirements for research using patient data might be waived; these must take into 
account the degree of anonymisation. The Department of Health's proposal to set up a 
national confidentiality and security advisory body, which was announced on 15 March, is 
welcome.20 This new body should have the potential to provide the necessary clear guidance 
for research, similar to the guidance in the United States on disclosure of individually 
identifiable health data for research under specified conditions.
12
 
Conclusion 
Researchers performing epidemiological studies in the United Kingdom need clear guidance 
in several areas. Firstly, the definition of explicit consent and the situations in which it is 
required need further explanation. Secondly, there is an unacceptable amount of uncertainty 
over when consent can be considered to have been implied or when it may be waived on 
grounds of public interest. Research ethics committees may be asked to advise on whether 
processing identifiable data without consent is in the public interest. This is an onerous 
responsibility, especially in light of the uncertainties described in this paper. The Department 
of Health's ongoing review of guidelines for local research ethics committees will help 
illuminate this situation. The legal responsibility lies ultimately with the trust, and any 
decision regarding disclosure must be able to be justified as being in the public interest. 
Thirdly, anonymisation and its effects need to be clarified especially taking into account the 
court case described earlier. Fourthly, issues of access to confidential data must be resolved. 
The effect of a contract between the NHS and outside research staff also needs to be clarified 
(for example, in cases in which research staff are funded by the NHS itself or when they have 
an NHS contract with some, but not all, of the trusts involved in a multicentre research 
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study). Ultimately, the legality of any guidance or decision can only be determined by the 
courts. 
In the meantime, a workable solution that respects patients' rights may be to ensure that data 
are fully anonymised whenever possible. In this case, the data is not personal and does not 
fall within the scope of the Data Protection Act. If full anonymisation is not possible or the 
design of the study does not permit it, the use of pseudonymous data (created using codes and 
carefully restricting access to them) should be considered, bearing in mind that it is still seen 
by the data protection registrar as personal data. To facilitate future research, trusts need to 
ensure that sufficient mechanisms are in place to inform patients about any potential use of 
their data for research and to obtain consent when necessary. Finally, researchers should 
agree their project design with those responsible for data protection well in advance. 
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